Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Technical Presentation (May 2020)
10 slides from Arbutus Biopharma's technical presentation, May 18, 2020
Slide 1: AB-729-001 60mg Week 12 Results
AB-729-001 60mg Week 12 Results May 18, 2020 NASDAQ: ABUS www.arbutusbio.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward- looking information within the meaning of Canadian securities laws (collectively,
Slide 3: AB-729-001 Study Design
AB-729-001 Study Design PART 1: Single Ascending Dose PART 2: Single Doses PART 3: Multiple Doses In Healthy Subjects In Chronic Hepatitis B Subjects In Chronic Hepatitis B Subjects Dose 1 (60mg) Cohort A: 180mg Cohort E: 60mg Q4W n=6; 4 active : 2 placebo HBV DNA - n=6 HBV DNA - n=7 (≥ Day 15 Safet
Slide 4: Key Inclusion/Exclusion Criteria
AB-729-001 Key Inclusion/Exclusion Criteria 1. Documented chronic hepatitis B infection; confirmed HBeAg positive or negative 2. HBV-DNA at screening: a) For HBV-DNA negative subjects (on a NA for at least 6 months): HBV-DNA <LLOQ b) For HBV-DNA positive subjects: HBV-DNA ≥1,000 IU/mL 3. HBsAg ≥250
Slide 5: Chronic Hepatitis B Subject Demographics
AB-729-001 Chronic Hepatitis B Subject Demographics Cohort A: 180mg (n=4) Cohort B: 60mg (n=6) Age (mean, range) 42.8 (35-53) 48.2 (33-56) Male Gender (n, percentage) 3 (75%) 3 (50%) Asian Race (n, percentage) 0 (0%) 3 (50%) Hepatitis B e-Antigen Negative (n, percentage) 3 (75%) 6 (100%) Baseline He
Slide 6: Continuous Mean HBsAg Decline of ~1 log10 with a Single 60 mg Dose
Continuous Mean HBsAg Decline of ~1 log10 with a Single 60 mg Dose Matching HBsAg Decline of 180 mg at Week 12 0.25 AB-729 60 mg (N=6) 0.25 AB-729 180 mg (N=4) 0 0 - 0.99 log10 - 0.98 log -0.25 -0.25 10 IU/mL IU/mL -0.5 -0.5 -0.75 -0.75 -1 -1 -1.25 -1.25 -1.5 -1.5 0 14 28 42 56 70 84 0 14 28 42 56 7
Slide 7: All Subjects Responded in the 60mg Single-Dose Cohort
All Subjects Responded in the 60mg Single-Dose Cohort Minimum HBsAg decline of -0.62 log10 and maximum HBsAg decline of -2.14 log10 at week 12 AB-729 60 mg (N=6) AB-729 180 mg (N=4) 0.5 0.5 0 0 -0.5 -0.5 -1 -1 -1.5 -1.5 -2 -2 -2.5 -2.5 0 14 28 42 56 70 84 0 14 28 42 56 70 84 NASDAQ: ABUS www.arbutus
Slide 8: AB-729 60mg Single-dose Generally Safe and Well Tolerated with Normal ALT/AST
AB-729 60mg Single-dose Generally Safe and Well Tolerated with Normal ALT/AST Through 12 Weeks Alanine Aminotransferase Aspartate Aminotransferase 450 450 400 400 350 350 300 300 250 250 200 200 150 150 100 100 Upper Limit Normal = 48 Upper Limit Normal = 40 50 50 0 0 0 14 28 42 56 70 84 0 14 28 42
Slide 9: AB-729 Next Steps
AB-729 Next Steps Preliminary Data Cohort Status Anticipated 60 mg multi-dose (Dose Interval = 4 weeks) Ongoing 2H 2020 60 mg multi-dose (Dose Interval = 8 weeks) Initiate ASAP 2H 2020 90 mg single-dose Ongoing 2H 2020 NASDAQ: ABUS www.arbutusbio.com
Slide 10: Q&A
“YArbutus BIOPHARMA Q&A
Arbutus Biopharma — Technical Presentation (May 2020) on 6ix